PreciseDx AI platform improves breast cancer grading, risk categorization, and outcome predictions.
PreciseDx, a leading innovator in AI-powered, patient-specific disease analysis, has recently published a paper in Breast Cancer Research, demonstrating the ability of its digital AI platform to enrich breast cancer grading and improve risk categorization. The paper, entitled ‘Development and Validation of an AI-Enabled Digital Breast Cancer Assay to Predict Early-Stage Breast Cancer Recurrence Within 6 Years,’ illustrates an industry-changing advancement in cancer diagnosis and outcome predictions.
Despite advances in breast cancer screening and diagnosis, there still remains an opportunity to improve accuracy in histologic characterization, grading and prognosis. PreciseDx’s Platform, which leverages its Morphology Feature Array, has proven the ability to enhance pathology interpretation with objective, quantifiable, and highly accurate data. This provides more robust information regarding patient disease status, representing the next generation of pathology analysis.
A population-based longitudinal clinical development and validation study was conducted to examine more than 2,000 patients from Mount Sinai Hospital with infiltrating ductal carcinoma of the breast. Following patients retrospectively for a median of six years, the study determined the PreciseDx Platform improved risk stratification and prediction of disease recurrence over standard histologic grade and clinical features, and demonstrated the ability to supplement molecular genomic tests.
The publication in Breast Cancer Research on the clinical validation of the AI-enabled digital assay to predict early-stage breast cancer recurrence marks a key milestone in advancing the automated AI-driven platform to phenotype and grade invasive breast cancer with just an Hematoxylin and Eosin (H&E) image and readily available clinical data. Additional extended validation studies are underway to enrich the current results and broaden access to this platform throughout the breast cancer community.
PreciseDx’s Platform has the potential to revolutionize the way cancer is diagnosed and treated, providing more accurate and reliable information for pathologists, oncologists and patients alike. This advancement in cancer diagnosis and outcome predictions is a welcome step in the right direction for the medical community.